Bevacizumab plus Docetaxel

2 trials

Sponsors

Cancer Institute Hospital Japanese Foundation for Cancer Research, Thoracic Oncology Research Group(TORG)

Conditions

Non-small cell lung cancerPreviously treated advanced NSCLC(non-squamous)

Unknown Phase

Feasibility study of Docetaxel plus Bevacizumab in selected patient with previously treated advanced NSCLS(non-squamous).

Active, not recruitingJPRN-UMIN000003397

Cancer Institute Hospital Japanese Foundation for Cancer ResearchPreviously treated advanced NSCLC(non-squamous)

Start: 2010-04-01Target: 15Updated: 2026-06-29

A feasibility study of Docetaxel/Bevacizumab in elderly patients with advanced non-small cell lung cancer (TORG1014)

Active, not recruitingJPRN-UMIN000004240

Thoracic Oncology Research Group(TORG)Non-small cell lung cancer

Start: 2010-09-01Target: 12Updated: 2026-06-29

Related Papers

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.

2015-10-195 citations